Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized adjunctive placebo-controlled trial of YKP3089 for treatment-resistant partial-onset seizures
2011-000901-37Phase 2Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing YKP3089 adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoint: Percent change in seizure frequency. Started Feb 2012; status: completed.
02
Drugs
cenobamate
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2011-000901-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000901-37.